English
Home > Products > Phosphatidylserine API

China Phosphatidylserine API Factory

We emphasize advancement and introduce new products into the market each year for Phosphatidylserine API,CAS NO 51446-62-9,51446-62-9,Phosphatidylserine, Good quality, timely service and Competitive price, all win us a good fame in xxx field despite the international intense competition.
Phosphatidylserine API, The best and original quality for spare parts is a most important factor for transportation. We may stick on supplying original and good quality parts even a little profit earned. God will bless us to do kindness business forever.

Related Products

Hot Products

  • Sulbactam sodium

    Sulbactam sodium

    Product Name:Sulbactam sodium
    Molecular Formula:C8H12NNaO5S
    Molecular Weight;257.24
    CAS Registry Number;69388-84-7
  • OXANTEL PAMOATE

    OXANTEL PAMOATE

    Product Name:OXANTEL PAMOATE
    Molecular Formula:C49H48N4O8
    Molecular Weight:820.93
    CAS Registry Number:68813-55-8
  • Resveratrol

    Resveratrol

    Product Name:Resveratrol
    Molecular Formula:C14H12O3
    Molecular Weight:228.24
    CAS Registry Number:501-36-0
  • Testosterone enanthate

    Testosterone enanthate

    Product Name:Testosterone enanthate
    Molecular Formula:C26H40O3
    Molecular Weight:400.59
    CAS Registry Number;315-37-7
  • 2-Chloro-6-fluorobenzaldehyde

    2-Chloro-6-fluorobenzaldehyde

    Product Name:2-Chloro-6-fluorobenzaldehyde
    Molecular Formula:C7H4ClFO
    Molecular Weight:158.56
    CAS Registry Number:387-45-1
  • 2-(2-Oxo-butyl)-cyclohexane-1,3-dione

    2-(2-Oxo-butyl)-cyclohexane-1,3-dione

    Product Name:2-(2-Oxo-butyl)-cyclohexane-1,3-dione
    Molecular Formula:C10H14O3
    Molecular Weight:182.22
    CAS Registry Number:24836-98-4
  • Related Blog
  • Reviews

  • Bosutinib CAS 380843-75-4

    Chemical name:4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • Gilteritinib Fumarate

    Sandoo Pharmaceutica is a professional pharmaceutical intermediates manufacturer. We provide good quality Gilteritinib Fumarate Cas: 1254053-43-4. Welcome and we look forward to your inquiry!

  • What Is Ursodeoxycholic Acid Used For?

    Ursodeoxycholic acid is a cholelithiant commonly used in the gastroenterology department, and also a cholelithiasis dissolving agent, so it can be used in the treatment of gallstones under normal circumstances, on the premise...

  • How to find the best China API manufacturer?

    Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept